全身皮质类固醇在眶蜂窝织炎治疗中的作用:美国眼科学会报告
本报告由美国眼科学会综述全身皮质类固醇治疗眶蜂窝织炎的安全性与获益,纳入9项原始研究(证据等级I级1项、II级4项、III级4项)。研究用药方案异质,部分报告住院时间缩短但更大研究未重复;2项研究显示症状缓解更快,多数研究手术干预与再入院率无差异;不良事件罕见且似自限,但报告不充分。
要点
- 全身皮质类固醇在眶蜂窝织炎中可能安全,或加快症状缓解。
- 对住院时间的影响尚不明确,较大研究未重复缩短住院的获益。
- 多数研究报告手术干预率和再入院率与未用药者相当。
核心结论
- 全身皮质类固醇在眶蜂窝织炎中可能安全,并可能改善症状缓解速度。
- 皮质类固醇对住院时间的影响仍不明确。
- 现有证据缺乏标准化,许多研究未专门报告不良事件发生率。
研究设计与样本
- 美国眼科学会系统综述,检索PubMed截至2025年8月。
- 纳入英文原始研究、至少10例患者、专门评估眶蜂窝织炎接受全身皮质类固醇的结局。
- 初检获104篇,9篇全文符合纳入标准并由方法学家评定证据等级。
主要发现
- 证据等级:I级1项、II级4项、III级4项。
- 各研究全身皮质类固醇的剂量方案和疗程不一。
- 部分研究报告住院时间缩短,但较大研究未能重复此获益。
- 2项专门评估症状缓解的研究显示用药者症状缓解更快。
- 多数研究报告手术干预率和再入院率在用药与未用药患者中相当;不良事件罕见且似自限,但许多研究未专门报告。
关键数值与推荐
- 纳入标准:英文原始研究、至少10例患者、专门评估眶蜂窝织炎患者接受全身皮质类固醇的结局。
- 证据等级分布:I级1项、II级4项、III级4项。
临床怎么用
- 眶蜂窝织炎可考虑使用全身皮质类固醇,但需注意证据异质性和不良事件报告不足。
- 不应以缩短住院时间为目的常规使用皮质类固醇,因证据不明确。
- 使用皮质类固醇时仍需按常规评估手术干预指征,因多数研究显示手术率无差异。
局限性
- 纳入研究用药剂量方案和疗程不一致,缺乏标准化。
- 许多研究未专门报告不良事件发生率。
- 部分结局(如住院时间)在不同规模研究中结果不一致。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To review the literature on the benefits and risks of systemic corticosteroids in the setting of orbital cellulitis. METHODS: A literature search was last performed in the PubMed database in August 2025. Articles were limited to original research in the English language that included at least 10 patients and specifically assessed outcomes in patients with orbital cellulitis who received systemic corticosteroids. The initial search yielded 104 articles; 9 articles were reviewed in full text and met all of the criteria for inclusion for this assessment. The panel methodologist assigned a level of evidence rating to each of the studies. RESULTS: One study was rated level I, 4 studies were rated level II, and 4 studies were rated level III. The studies included in this assessment used variable dosing patterns and durations of systemic corticosteroids. Some studies reported shorter lengths of hospitalization when these agents were used, but larger studies failed to replicate this benefit. Although patients who received corticosteroids experienced faster resolution of symptoms in the 2 studies that specifically assessed this metric, most studies reported equal rates of surgical intervention and hospital readmission among patients who did and did not receive it. Adverse events were rare and seemed to be self-limited at the doses used, although many studies did not specifically report these complications. CONCLUSIONS: The available evidence examining the effectiveness of systemic corticosteroids showed a lack of standardization, and many studies did not specifically report the rates of adverse events. Nevertheless, systemic corticosteroids may be safe in the setting of orbital cellulitis and may improve the rate of symptom resolution. The impact of corticosteroids on duration of hospitalization remains unclear. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
引用
- Wladis EJ, Aakalu VK, Dagi Glass LR, et al. The Role of Corticosteroids in the Management of Orbital Cellulitis: A Report by the American Academy of Ophthalmology. Ophthalmology. 2026. PMID: 42053485. doi:10.1016/j.ophtha.2026.03.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。